ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SNG Synairgen Plc

4.65
0.00 (0.00%)
Last Updated: 10:52:51
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.65 4.52 4.99 - 189,060 10:52:51
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.36M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.65p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.36 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 19201 to 19220 of 99175 messages
Chat Pages: Latest  775  774  773  772  771  770  769  768  767  766  765  764  Older
DateSubjectAuthorDiscuss
31/7/2020
12:53
Would PHE allow a small scale approval for certain cases?
trinitygooner
31/7/2020
12:38
We won't get a collective statement from regulators as they don't act together but in isolation. The most likely to hear from first is the MHRA but I wouldn't guarantee it. I wouldn't be surprised if the FDA trump (no pun intended) them just because they seem to be more on the ball at the moment!
nobbygnome
31/7/2020
12:32
I do not think a formal phase 3 trial will be needed. Just a conditional approval with careful monitoring and reporting by clinicians. The SNG product was used recently in a home trial then there is already some good background evidence to suggest this is the case. Such is the human need and this treatment is very safe as shown by many global scientific papers over many years. I don't think its long until some sort of collective statement by regulators in this regard. I'm guessing sometime during the next 10 to 14 days we are supplying product to the masses. The only limit is how quickly we can supply the neb. kit and drug formulation.
elsol
Chat Pages: Latest  775  774  773  772  771  770  769  768  767  766  765  764  Older